drugset
drugset / Trial / NCT01745367

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

NCT01745367 ↗

Phase 2 Terminated 30 enrolled AVEO Pharmaceuticals, Inc. Astellas Pharma Inc · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.

Timeline

Start
2012-11
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivozanib Small molecule 1.5 mg Oral
Background Paclitaxel Small molecule 90 mg/m2 Intravenous

Indications

triple-negative breast carcinoma